DL-8280の臨床的検討

武田 元; 庭山 昌俊; 岩永 守登; 田中 容; 和田 光一; 森本 隆夫; 小林 次雄; 荒川 正昭

doi:10.11250/chemotherapy1953.32.Supplement1_204

CLINICAL STUDIES ON DL-8280

HAZIMU TAKEDA, MASATOSHI NIWAYAMA, MORITO IWANAGA, Yo TANAKA, KOUICHI WADA, TAKAO MORIMOTO, TSUGUO KOBAYASHI, MASAAKI ARAKAWA

Author information

HAZIMU TAKEDA
Department of Internal Medicine (II), Niigata University, School of Medicine
MASATOSHI NIWAYAMA
Department of Internal Medicine (II), Niigata University, School of Medicine
MORITO IWANAGA
Department of Internal Medicine (II), Niigata University, School of Medicine
Yo TANAKA
Department of Internal Medicine (II), Niigata University, School of Medicine
KOUICHI WADA
Department of Internal Medicine (II), Niigata University, School of Medicine
TAKAO MORIMOTO
Department of Internal Medicine (II), Niigata University, School of Medicine
TSUGUO KOBAYASHI
Department of Internal Medicine (II), Niigata University, School of Medicine
MASAAKI ARAKAWA
Department of Internal Medicine (II), Niigata University, School of Medicine

JOURNAL FREE ACCESS

1984 Volume 32 Issue Supplement1 Pages 204-208

DOI https://doi.org/10.11250/chemotherapy1953.32.Supplement1_204

Details

Abstract

DL-8280 was orally administrated to 5 patients with urinary tract infection and 8 patients with respiratory tract infection. The patients received the drug for 7 to 21 days in dose of 300 to 600 mg/day. All patients with urinary tract infection and respiratory tract infection responded well to the therapy.
No side effect of DL-8280 was recognized.

Corresponding author

Register with J-STAGE for free!